Cover Image
市場調查報告書

尋常型天皰瘡:開發中產品分析

Pemphigus Vulgaris - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213128
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
尋常型天皰瘡:開發中產品分析 Pemphigus Vulgaris - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 50 Pages
簡介

尋常型天皰瘡,是少見的自體免疫疾病,有疼痛的水痘皮膚或粘膜發生。人種,性別,年齡等風險要素,症狀疼伴隨的水痘開端出現口內喪失。水痘在通常皮膚表面附近出現,體液的滲出,痂皮形成,脫皮等。

本報告提供尋常型天皰瘡的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

尋常型天皰瘡概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Almirall SA
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc

藥物簡介

尋常型天皰瘡:暫停中的計劃

尋常型天皰瘡:開發中止的產品

尋常型天皰瘡:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9328IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H1 2017, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pemphigus Vulgaris - Overview
    • Pemphigus Vulgaris - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pemphigus Vulgaris - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pemphigus Vulgaris - Companies Involved in Therapeutics Development
    • Almirall SA
    • Biogen Inc
    • HanAll Biopharma Co Ltd
    • Immunomedics Inc
    • Novartis AG
    • Principia Biopharma Inc
  • Pemphigus Vulgaris - Drug Profiles
    • ADP-31415 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRN-1008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYNT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAY-736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pemphigus Vulgaris - Dormant Projects
  • Pemphigus Vulgaris - Discontinued Products
  • Pemphigus Vulgaris - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris
      • Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology
      • Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pemphigus Vulgaris, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pemphigus Vulgaris - Pipeline by Almirall SA, H1 2017
  • Pemphigus Vulgaris - Pipeline by Biogen Inc, H1 2017
  • Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H1 2017
  • Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2017
  • Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H1 2017
  • Pemphigus Vulgaris - Dormant Projects, H1 2017
  • Pemphigus Vulgaris - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Pemphigus Vulgaris, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top